Fact checked by Jennifer Klump Key Takeaways Insulin costs have declined over the past two years, and additional price cuts ...

(Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with ...

New data reveals that Januvia was as effective as Glucotrol in reducing blood sugar levels in patients with type 2 diabetes.Merck (NYSE: MRK) announced today its drug Januvia was as effective as the ...

Diabetics gained a new way of controlling their blood sugar levels Tuesday with the federal approval of a novel pill for Type 2 diabetes, which affects about 20 million Americans. The Food and Drug ...

CHICAGO, June 23 (Reuters) - Merck & Co.'s new diabetes pill, Januvia, improved blood sugar control when added to current therapies, according to data released on Saturday at a major medical meeting.

Washington - Diabetics gained a new way of controlling their blood sugar levels Tuesday with the federal approval of a novel pill for Type 2 diabetes, which affects about 20 million Americans. The ...

Although designed to treat Type 2 diabetes, some medications have been involved recently in diabetes drug lawsuits. LawyersandSettlements.com, the nation's premier publication for online legal news ...

The ITCA 650 device, which delivers tiny doses of exenatide, could be a game changer in solving the problem of medication adherence. An application for FDA approval is expected in the first half of ...

Patients treated with ITCA 650 60mcg experienced superior reductions in HbA1c versus those treated with Januvia® (sitagliptin) 100mg (-1.5% versus -0.8%; p<0.001) ITCA 650 60mcg produced significantly ...

In particular, Januvia for diabetes, Isentress for HIV, and the Gardasil vaccine against human papillomavirus represent new blockbusters. All the drugs enjoyed monopoly positions at the time of launch ...

After years of battling over the patents on blockbuster diabetes drug Januvia, Merck and its generic rival Viatris are ready to put the case to rest. In a recent filing with the U.S. District Court ...